Table 3.
Haplotype analysis for the VEGF polymorphisms 1451C>T, 1612G>A and 1725G>A in RPL patients and controls.
| Haplotype | Controls (2n = 472) | RPL Patients (2n = 756) | OR (95% CI) | p a | p b |
|---|---|---|---|---|---|
| VEGF 1451/1612/1725 | |||||
| C-G-G | 300 (63.6) | 505 (66.8) | 1.000 (reference) | ||
| C-G-A | 6 (1.3) | 1 (0.1) | 0.099 (0.012–0.827) | 0.013 | 0.026 |
| C-A-G | 53 (11.2) | 75 (9.9) | 0.841 (0.575–1.229) | 0.379 | 0.386 |
| C-A-A | 34 (7.2) | 29 (3.8) | 0.507 (0.303–0.849) | 0.011 | 0.026 |
| T-G-G | 75 (15.9) | 146 (19.3) | 1.156 (0.846–1.582) | 0.386 | 0.386 |
| T-G-A | 0 (0.0) | 0 (0.0) | N/A | N/A | N/A |
| T-A-G | 4 (0.8) | 0 (0.0) | 0.066 (0.004–1.232) | 0.020 | 0.033 |
| T-A-A | 0 (0.0) | 0 (0.0) | N/A | N/A | N/A |
| VEGF 1451/1612 | |||||
| C-G | 305 (64.6) | 506 (66.9) | 1.000 (reference) | ||
| C-A | 88 (18.6) | 104 (13.8) | 0.712 (0.519–0.979) | 0.040 | 0.060 |
| T-G | 75 (15.9) | 146 (19.3) | 1.173 (0.858–1.604) | 0.345 | 0.345 |
| T-A | 4 (0.8) | 0 (0.0) | 0.067 (0.004–1.250) | 0.020 | 0.060 |
| VEGF 1451/1725 | |||||
| C-G | 353 (74.8) | 580 (76.7) | 1.000 (reference) | ||
| C-A | 40 (8.5) | 30 (4.0) | 0.457 (0.279–0.746) | 0.002 | 0.004 |
| T-G | 79 (16.7) | 146 (19.3) | 1.125 (0.830–1.525) | 0.490 | 0.490 |
| T-A | 0 (0.0) | 0 (0.0) | |||
| VEGF 1612/1725 | |||||
| G-G | 374 (79.2) | 651 (86.1) | 1.000 (reference) | ||
| G-A | 6 (1.3) | 1 (0.1) | 0.096 (0.011–0.799) | 0.012 | 0.018 |
| A-G | 58 (12.3) | 75 (9.9) | 0.743 (0.525–1.071) | 0.127 | 0.127 |
| A-A | 34 (7.2) | 29 (3.8) | 0.490 (0.294– 0.817) | 0.007 | 0.018 |
Abbreviations: RPL, recurrent pregnancy loss; OR, odds ratio. a Fisher’s exact test. b False discovery rate-adjusted p-value for multiple hypotheses testing using the Benjamini–Hochberg method. Acceptance of statistical significance at p < 0.05 and 95% confidence interval not including 1.